AVBP
ArriVent BioPharma, Inc.Closed16.09−0.37 −2.25%USD
NasdaqGM · as of Oct 13, 16:00 ET · 15m delayAfter hours 16.37 +1.74%
Open
16.28
Prev close
16.46
Day range
15.9516.72
52-week range
11.3635.83
Volume
1.97M2.06×
Mkt cap
793.36M
P/E ttm
—
Fwd P/E
-4.15
EPS ttm
-3.62
Div yield
0.00%
Earnings
—
From 52w high
−55.09%
AVBP earnings and estimates
AVBP Next Report
Yahoo Finance · Nasdaq
Report date
Mon, Nov 16
After the close · estimated
EPS consensus
$−1.08
range −1.22 – −1.00
EPS growth vs year ago
−29.8%
year ago −0.83
Revenue consensus
$0
0.0% vs year ago
Options-implied move
±29.7%
by Nov 20 · ATM straddle
Past 4 reactions
±3.8%
average move · beat 1 of 4
EPS: Actual vs Estimate
Price Reaction
close before → close after the report
Recent Reports
| Quarter ending | Reported | EPS | Estimate | Surprise | Revenue | Next session | Five sessions |
|---|---|---|---|---|---|---|---|
| Jun '26 | Aug 12, 2026 AMC | −1.05 | −0.98 | −6.73% | — | −4.6% | −4.6% |
| Mar '26 | May 11, 2026 AMC | −0.96 | −0.89 | −7.40% | $0 | −0.2% | −6.8% |
| Dec '25 | Mar 5, 2026 AMC | −0.78 | −0.85 | +7.69% | $0 | −7.2% | −4.6% |
| Sep '25 | Nov 10, 2025 BMO | −0.83 | −0.78 | −6.02% | $0 | +3.1% | +14.7% |
Consensus Estimates and Revisions
| Period | EPS | Low · range · high | Growth | Revenue | Growth | 30d ago | 90d ago | Up / down (30d) |
|---|---|---|---|---|---|---|---|---|
| Current quarter Sep 2026 | −1.08 | −1.22−1.00 | −29.8% | $0 | 0.0% | −1.07 −0.3% | −0.97 −11.4% | 0 / 7 |
| Next quarter Dec 2026 | −1.10 | −1.54−0.90 | −40.6% | $0 | 0.0% | −1.13 +3.3% | −0.99 −11.1% | 1 / 6 |
| Current year Dec 2026 | −4.22 | −4.94−3.90 | +2.3% | $0 | 0.0% | −4.34 +2.8% | −4.02 −4.9% | 1 / 6 |
| Next year Dec 2027 | −3.87 | −4.80−3.10 | +8.2% | $7.31M | 0.0% | −3.81 −1.8% | −3.50 −10.7% | 3 / 4 |
The change columns show how the consensus has moved since then; steady upward revisions often precede beats. Ranges place the consensus between the lowest and highest analyst estimate.
Forward EPS Forecasts
Nasdaq · Zacks consensus
Quarterly
| Fiscal period | Consensus | Low · range · high | Analysts | Up / down (4w) |
|---|---|---|---|---|
| Sep 2026 | −1.06 | −1.09−1.02 | 3 | 1 / 0 |
| Dec 2026 | −1.05 | −1.08−1.02 | 3 | 1 / 0 |
| Mar 2027 | −0.93 | −0.96−0.89 | 2 | 2 / 0 |
| Jun 2027 | −0.93 | −0.98−0.88 | 2 | 2 / 0 |
| Sep 2027 | −0.92 | −1.00−0.83 | 2 | 2 / 0 |
Fiscal years
| Fiscal period | Consensus | Low · range · high | Analysts | Up / down (4w) |
|---|---|---|---|---|
| Dec 2026 | −4.05 | −4.19−3.90 | 5 | 1 / 1 |
| Dec 2027 | −3.82 | −4.80−3.10 | 4 | 2 / 1 |
| Dec 2028 | −1.63 | −4.080.82 | 2 | 1 / 0 |
| Dec 2029 | 1.05 | −1.934.03 | 2 | 1 / 0 |
Reactions run from the last close before a report to the first close after it (an after-the-close report is measured to the next day's close). The implied move is the at-the-money straddle for the first expiry after the report, the same rule as the bot's lgf emove.